Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
141.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 3.00 (2.143%)
Market Cap: £119.75m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Expanded lab network and data capabilities

27 Feb 2024 07:00

RNS Number : 5258E
Diaceutics PLC
27 February 2024
 

Diaceutics grows its lab network and data capabilities in Europe

 

New data will deliver enhanced insights to Diaceutics' customers and drive new sales opportunities across multiple geographies

 

Belfast and London, 27 February 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce it has expanded its data supply network which will significantly increase the number of labs through which Diaceutics is sourcing data in Europe and will broaden the Company's European data coverage. This data will accelerate the rollout of the DxRx Signal product in key EU markets of Germany, France, Italy, Spain and the United Kingdom (DxRx Signal has only previously been offered by Diaceutics in the US market).

The increased data is now available to Diaceutics customers enabling them to find more patients eligible for their new and innovative therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "This data will further endorse our position as a leading provider of data to biotech and pharma companies as they commercialize their products, find and deliver therapies to patients across multiple geographies."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer. 

 

Enquiries: 

Diaceutics PLC?

 Tel: +44 (0)28 9040 6500 

Ryan Keeling, Chief Executive Officer 

Nick Roberts, Chief Financial Officer

Jordan Clark, Chief Data Officer

investorrelations@diaceutics.com 

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 

Nick Harland 

Kate Hanshaw 

Alma Strategic Communications 

Tel: +44 (0)20 3405 0205 

Caroline Forde 

diaceutics@almastrategic.com 

Kinvara Verdon 

 

About Diaceutics 

At Diaceutics we believe that?every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDXGDDDBDDGSL
Date   Source Headline
1st Jun 20262:00 pmRNSPDMR Shareholding/Share Incentive Plan & TVRs
29th May 20262:00 pmRNSNotice of AGM & Posting of Annual Report
26th May 20267:00 amRNSFinal Results
13th May 20267:00 amRNSNotice of Results
12th May 20262:00 pmRNSHolding(s) in Company
5th May 20267:00 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
16th Apr 20261:11 pmRNSRelated Party Transaction - Lease Extension
7th Apr 20267:00 amRNSBlock Listing Return
1st Apr 202611:59 amRNSPDMR Shareholding/SIP & Total Voting Rights
3rd Mar 202610:56 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
3rd Feb 20268:01 amRNSPDMR Shareholding/Share Incentive Plan & TVR
15th Jan 20267:00 amRNSFull Year 2025 Trading Update
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
28th Nov 202511:53 amRNSPDMR Shareholding/SIP & Total Voting Rights
4th Nov 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
7th Oct 20257:00 amRNSBlock listing Interim Review
1st Oct 202511:40 amRNSPDMR Shareholding/Share Incentive Plan and TVR
23rd Sep 20257:00 amRNSH1 2025 Results
11th Sep 20257:00 amRNSNotice of Results
9th Sep 202510:47 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
11th Aug 202510:58 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDiaceutics at Canaccord Genuity Growth Conference
30th Jul 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Jul 20257:00 amRNS-RDiaceutics Announces Key Leadership Appointment
25th Jul 202512:15 pmRNSHolding(s) in Company
23rd Jul 20257:00 amRNSIssue of Share Options / PDMR Shareholdings
22nd Jul 20257:00 amRNS22% Revenue Growth H125 representing 3-yr CAGR 25%
17th Jul 20257:00 amRNS-RExpansion of PMx Commercialization Partnership
30th Jun 20257:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
18th Jun 202512:00 pmRNSResults of AGM
6th Jun 20259:33 amRNSPDMR Shareholding /Share Incentive Plan and TVR
21st May 20255:00 pmRNSNotice of AGM and Posting of Annual Report
15th May 20257:00 amRNSTransaction by Persons Closely Associated to PDMRs
13th May 20257:00 amRNSFY 2024 Results - Strong Revenue Growth
29th Apr 20254:09 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Apr 20257:00 amRNSNotice of Results
7th Apr 202510:33 amRNSBlock Listing Return
3rd Apr 20251:54 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
26th Mar 20257:00 amRNSPMx Promotional Partner Contract Enhancement
6th Mar 20253:16 pmRNSHolding(s) in Company
3rd Mar 20253:00 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
31st Jan 20259:13 amRNSPurchase of Shares and PDMR Shareholding
30th Jan 202511:27 amRNSPDMR Shareholding/Share Incentive Plan
28th Jan 20257:00 amRNSFY 2024 Trading Update - Strong Revenue Growth
14th Jan 20257:00 amRNSDiaceutics Opens US Headquarters
8th Jan 20257:00 amRNSNew Service Launched & First Contract Signed
3rd Jan 20253:39 pmRNSPDMR Dealings & Total Voting Rights
19th Dec 20248:09 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.